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BACKGROUND
BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing– 
remitting multiple sclerosis, which is commonly treated with parenteral agents (in-
terferon or glatiramer acetate).
METHODS
In this phase 3, randomized study, we investigated the efficacy and safety of oral 
BG-12, at a dose of 240 mg two or three times daily, as compared with placebo in 
patients with relapsing–remitting multiple sclerosis. An active agent, glatiramer ac-
etate, was also included as a reference comparator. The primary end point was the 
annualized relapse rate over a period of 2 years. The study was not designed to test 
the superiority or noninferiority of BG-12 versus glatiramer acetate.
RESULTS
At 2 years, the annualized relapse rate was significantly lower with twice-daily BG-12 
(0.22), thrice-daily BG-12 (0.20), and glatiramer acetate (0.29) than with placebo 
(0.40) (relative reductions: twice-daily BG-12, 44%, P<0.001; thrice-daily BG-12, 51%, 
P<0.001; glatiramer acetate, 29%, P = 0.01). Reductions in disability progression with 
twice-daily BG-12, thrice-daily BG-12, and glatiramer acetate versus placebo (21%, 
24%, and 7%, respectively) were not significant. As compared with placebo, twice-
daily BG-12, thrice-daily BG-12, and glatiramer acetate significantly reduced the 
numbers of new or enlarging T2-weighted hyperintense lesions (all P<0.001) and new 
T1-weighted hypointense lesions (P<0.001, P<0.001, and P = 0.002, respectively). In post 
hoc comparisons of BG-12 versus glatiramer acetate, differences were not signifi-
cant except for the annualized relapse rate (thrice-daily BG-12), new or enlarging 
T2-weighted hyperintense lesions (both BG-12 doses), and new T1-weighted hypoin-
tense lesions (thrice-daily BG-12) (nominal P<0.05 for each comparison). Adverse 
events occurring at a higher incidence with an active treatment than with placebo 
included flushing and gastrointestinal events (with BG-12) and injection-related 
events (with glatiramer acetate). There were no malignant neoplasms or opportu-
nistic infections reported with BG-12. Lymphocyte counts decreased with BG-12.
CONCLUSIONS
In patients with relapsing–remitting multiple sclerosis, BG-12 (at both doses) and 
glatiramer acetate significantly reduced relapse rates and improved neuroradiologic 
outcomes relative to placebo. (Funded by Biogen Idec; CONFIRM ClinicalTrials.gov 
number, NCT00451451.)
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Multiple sclerosis is a chronic de-myelinating and neurodegenerative dis-ease of the central nervous system, which 
is commonly treated with parenteral agents (in-
terferon beta and glatiramer acetate). Oxidative 
stress and proinflammatory stimuli are important 
pathologic factors in multiple sclerosis.1-3 Experi-
mental data suggest that BG-12, an oral formula-
tion of dimethyl fumarate, has antiinflammatory 
and cytoprotective properties that are mediated 
through activation of the nuclear factor (erythroid-
derived 2)–like 2 transcriptional pathway, among 
others.3-6
Here, we report the results of the Comparator 
and an Oral Fumarate in Relapsing–Remitting 
Multiple Sclerosis (CONFIRM) trial, a randomized, 
multicenter, double-blind, 2-year study evaluat-
ing the efficacy and safety of BG-12, at a dose of 
240 mg two or three times per day, versus placebo 
in patients with relapsing–remitting multiple 
sclerosis. A rater-blinded, active agent approved for 
relapsing–remitting multiple sclerosis (subcutane-
ous glatiramer acetate at a dose of 20 mg per day) 
was also included as a reference comparator, to 
allow a relative benefit–risk assessment of BG-12 
through comparison of the active-treatment groups 
with the placebo group.
Me thods
STUDY OVERSIGHT
The study was approved by central and local ethics 
committees and conducted in accordance with 
the International Conference on Harmonization 
Guidelines for Good Clinical Practice7 and the 
Declaration of Helsinki.8 An advisory committee 
participated in study design and oversight of study 
conduct, a data and safety monitoring committee 
reviewed all pertinent benefit–risk data, and an 
independent neurologic evaluation committee, 
whose members were unaware of the study-group 
assignments, provided confirmation of relapses 
of multiple sclerosis (see the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org). Data were gathered by the investi-
gators and were analyzed by the sponsor (Biogen 
Idec), and data remained confidential during the 
study. All the authors were involved in all stages 
of manuscript development and vouch for the 
completeness and accuracy of the data. The first 
draft was cowritten by the first and last authors 
(the latter is a representative of the sponsor), 
with assistance from a medical-communications 
agency paid by the sponsor. The study was con-
ducted in accordance with the study protocol, 
which is available at NEJM.org.
PATIENTS
Key eligibility criteria were a diagnosis of relaps-
ing–remitting multiple sclerosis (McDonald cri-
teria9), an age of 18 to 55 years, a score of 0 to 5 on 
the Expanded Disability Status Scale (EDSS, which 
ranges from 0 to 10, with higher scores indicating 
greater disability),10 and at least one clinically doc-
umented relapse in the previous 12 months or at 
least one gadolinium-enhancing lesion 0 to 6 weeks 
before randomization. Key exclusion criteria were 
progressive forms of multiple sclerosis,11 other 
clinically significant illness, prespecified laborato-
ry abnormalities, and prior exposure to glatiramer 
acetate or contraindicated medications (see the 
Supplementary Appendix for additional details).
Patients were informed of approved therapies12 
for multiple sclerosis, and they provided written 
informed consent. Reconsent was required after 
a confirmed relapse or confirmed disability pro-
gression.
STUDY DESIGN
Patients at 200 sites in 28 countries were random-
ly assigned in a 1:1:1:1 ratio to receive oral pla-
cebo, BG-12 at a dose of 240 mg two times daily, 
BG-12 at a dose of 240 mg three times daily, or 
subcutaneous daily injections of 20 mg of gla tir-
a mer acetate for 96 weeks (Fig. S1 in the Supple-
mentary Appendix). Patients receiving gla tir a mer 
acetate were aware of their treatment assignment. 
All study management and site personnel, investi-
gators, and patients were unaware of assignment 
to the BG-12 and placebo groups; examining neu-
rologists, technicians at the magnetic resonance 
imaging (MRI) reading center, and members of 
the independent neurologic evaluation committee 
were unaware of all study-group assignments. Each 
site used separate examining and treating neurol-
ogists, thereby maintaining rater blinding for all 
study groups, including the group that received 
gla tir a mer acetate. To ensure that the assignments 
to the BG-12 and placebo groups would not be 
revealed, patients in those groups were instructed 
not to take the study medication within 4 hours 
before each study visit, since a flushing reaction 
is known to be more common with BG-12.13 Pa-
tients could switch to an alternative medication 
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for multiple sclerosis if they had two confirmed 
relapses and had completed 48 weeks of study 
treatment or if they had confirmed disability pro-
gression (see the Supplementary Appendix).
STUDY PROCEDURES AND END POINTS
Standardized neurologic assessments, including an 
EDSS assessment, were performed every 12 weeks 
and at the time of suspected relapse (evaluated 
during unscheduled visits). MRI scans were ob-
tained in a subset of patients at sites with MRI 
capabilities, at screening and at weeks 24, 48, and 
96, and were evaluated in a blinded manner at a 
central MRI reading center.
The primary efficacy end point was the annu-
alized relapse rate at 2 years, based on protocol-
defined relapses (new or recurrent neurologic 
symptoms not associated with fever or infection, 
lasting at least 24 hours, accompanied by new 
objective neurologic findings, and separated from 
the onset of other confirmed relapses by at least 
30 days) that were confirmed by the independent 
neurologic evaluation committee. Secondary ef-
ficacy end points included the number of new or 
enlarging hyperintense lesions on T2-weighted 
images, the number of new hypointense lesions on 
T1-weighted images, the proportion of patients 
with a relapse, and the time to disability progres-
sion, each at 2 years. Disability progression was 
defined as an increase in the EDSS score of at 
least 1.0 point in patients with a baseline score of 
1.0 or more or an increase of at least 1.5 points 
in patients with a baseline score of 0, confirmed 
at least 12 weeks later. Tertiary end points in-
cluded a comparison of the relative benefits and 
risks of BG-12 or gla tir a mer acetate versus placebo 
and the number of gadolinium-enhancing lesions 
at 2 years (see the Supplementary Appendix).
STATISTICAL ANALYSIS
We estimated that a sample of 308 patients per 
group would provide approximately 84% power at 
a two-sided significance level of 0.05 to detect a 
25% relative reduction in the 2-year annualized 
relapse rate, with the assumption of an annual-
ized relapse rate of 0.61 in the placebo group. A 
sequential (closed) testing procedure was used to 
control for overall type I error due to multiple 
comparisons (see the Supplementary Appendix).
Primary and secondary end points were ana-
lyzed in the intention-to-treat (ITT) population 
(all randomly assigned patients who received 
study treatment) and in the MRI cohort (patients 
in the ITT population for whom any postbase-
line MRI data were available), with the use of 
two-sided statistical tests at a significance level 
of 0.05.
The annualized relapse rate (total number of 
relapses divided by patient-years in the study, ex-
cluding data obtained after patients switched to 
alternative multiple sclerosis medications) was an-
alyzed with the use of a negative binomial re-
gression model adjusted for baseline EDSS score, 
age, region (regions were defined on the basis of 
not only geography but also the type of health care 
system and access to health care in each coun-
try), and number of relapses in the 12 months 
before study entry. Four sensitivity analyses were 
performed (see the Supplementary Appendix).
Negative binomial regression was used for 
analysis of the total number of new or enlarging 
hyperintense lesions on T2-weighted images and 
the total number of new hypointense lesions on 
T1-weighted images at 2 years. A Cox proportional-
hazards model was used for analysis of the pro-
portion of patients with clinical relapse and the 
time to disability progression. Models were ad-
justed for region, EDSS score, age, relapse rate, 
and volume of lesions, as appropriate.
In general, analyses of primary and secondary 
end points were based on all observed data before 
patients switched to alternative multiple sclerosis 
medications, with analyses of MRI end points 
additionally based on missing data imputed with 
the use of a constant-rate assumption. The study 
was not designed to test the superiority or non-
inferiority of BG-12 versus gla tir a mer acetate. 
Safety was analyzed with the use of descriptive 
statistics for the safety population (all patients who 
received at least one dose of the study medication), 
excluding data obtained after patients switched to 
alternative multiple sclerosis medications.
R esult s
PATIENTS
Of 1430 randomly assigned patients, 1417 were 
included in the ITT population (Fig. S2 in the Sup-
plementary Appendix). Baseline demographic and 
disease characteristics were similar among the 
four study groups (Table 1) and between the MRI 
cohort (681 patients) (Table S1 in the Supplemen-
tary Appendix) and non-MRI cohort (736 pa-
tients). Approximately 29% of patients had re-
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ceived an approved disease-modifying therapy 
before study entry.
Study completion rates were similar across 
study groups (overall rate in the ITT population, 
80%), with a mean time in the study of 86.1, 
84.4, 84.1, and 88.5 weeks in the placebo, twice-
daily BG-12, thrice-daily BG-12, and gla tir a mer 
acetate groups, respectively. The rate of study-
drug discontinuation was higher in the placebo 
group than in the other groups (36% vs. 30% in 
the twice-daily BG-12 group, 28% in the thrice-
daily BG-12 group, and 25% in the gla tir a mer 
acetate group) (Table S2 in the Supplementary 
Appendix), as was the proportion of patients who 
switched to alternative multiple sclerosis medica-
tions (11% vs. 7%, 8%, and 6%, respectively).
EFFICACY
Clinical End Points
The frequency of relapses of multiple sclerosis was 
significantly reduced by twice-daily and thrice-
daily BG-12, with an adjusted annualized relapse 
rate at 2 years (primary end point) of 0.22 and 
0.20, respectively, representing reductions relative 
to placebo (annualized relapse rate, 0.40) of 44% 
and 51% (P<0.001 for both comparisons). Gla tir-
a mer acetate also reduced the annualized relapse 
rate (0.29; relative reduction, 29% vs. placebo; 
Table 1. Baseline Demographic and Disease Characteristics (ITT Population).*
Characteristic
Placebo
(N = 363)
Twice-Daily BG-12  
(N = 359)
Thrice-Daily BG-12  
(N = 345)†
Glatiramer Acetate  
(N = 350)†
Age — yr 36.9±9.2 37.8±9.4 37.8±9.4 36.7±9.1
Female sex — no. (%) 251 (69) 245 (68) 250 (72) 247 (71)
Weight — kg 72.6±16.9 71.9±17.9 72.5±17.8 71.4±19.1
Race — no. (%)‡
White 305 (84) 304 (85) 292 (85) 290 (83)
Asian 28 (8) 28 (8) 26 (8) 25 (7)
Black 9 (2) 2 (<1) 5 (1) 11(3)
Other or unknown 21 (6) 25 (7) 22 (6) 24 (7)
Time since diagnosis — yr 4.8±5.0 4.9±5.1 4.6±5.2 4.4±4.7
Any prior approved DMT — no. (%)§ 111 (31) 101 (28) 100 (29) 103 (29)
Relapses in previous 12 mo — no. 1.4±0.8 1.3±0.6 1.4±0.7 1.4±0.6
EDSS score at baseline — no. (%)¶
0 13 (4) 15 (4) 15 (4) 18 (5)
1.0 or 1.5 78 (21) 85 (24) 84 (24) 77 (22)
2.0 or 2.5 111 (31) 94 (26) 94 (27) 96 (27)
3.0 or 3.5 98 (27) 105 (29) 99 (29) 99 (28)
4.0 or 4.5 50 (14) 47 (13) 42 (12) 46 (13)
5.0 13 (4) 12 (3) 11 (3) 14 (4)
Mean score on EDSS¶ 2.6±1.2 2.6±1.2 2.5±1.2 2.6±1.2
* All baseline characteristics were well balanced among the study groups (nominal P>0.05). Plus–minus values are means 
±SD. DMT denotes disease-modifying therapy, EDSS Expanded Disability Status Scale, and ITT intention to treat.
† One patient randomly assigned to the thrice-daily BG-12 group took glatiramer acetate throughout the study. This pa-
tient was counted in the thrice-daily BG-12 group of the ITT population and in the glatiramer acetate group of the safety 
population.
‡ Race was self-reported.
§ Prior exposure to interferon beta-1a (in 21% of the ITT population), interferon beta-1b (11%), natalizumab (1%), and 
glatiramer acetate (<1%) was balanced across groups; one patient was randomly assigned to glatiramer acetate who 
had previously been exposed to the drug. Patients may have received more than one prior multiple sclerosis medica-
tion. Patients may also have received other, nonapproved therapies for multiple sclerosis (the proportion of patients 
 receiving any multiple sclerosis medication before the study was 40 to 41% across study groups).
¶ Scores on the EDSS range from 0 to 10, with higher scores indicating a greater degree of disability. One patient in the 
twice-daily BG-12 group had a baseline score higher than 5.0.
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P = 0.01) (Fig. 1A and Table 2). Similar results were 
obtained in four sensitivity analyses that used 
different definitions of relapse or that included 
data after patients switched to alternative medi-
cations, findings that show the robustness of the 
results for the primary end point (Fig. S3 in the 
Supplementary Appendix).
As compared with placebo, twice-daily BG-12, 
thrice-daily BG-12, and gla tir a mer acetate signifi-
cantly reduced the risk of relapse, by 34% (P = 0.002), 
45% (P<0.001), and 29% (P = 0.01), respectively 
(Table 2). The Kaplan–Meier estimate of the pro-
portion of patients with a relapse at 2 years was 
41% in the placebo group as compared with 29%, 
24%, and 32% in the twice-daily BG-12, thrice-
daily BG-12, and gla tir a mer acetate groups, respec-
tively (Fig. S4 in the Supplementary Appendix). 
Similar findings were observed in sensitivity analy-
ses (Fig. S5 in the Supplementary Appendix).
Disability progression was not significantly 
reduced with twice-daily BG-12, thrice-daily BG-
12, or gla tir a mer acetate, as compared with 
placebo (relative reduction, 21% [P=0.25], 24% 
[P = 0.20], and 7% [P = 0.70], respectively) (Fig. 
1B and Table 2). The Kaplan–Meier estimate of 
the proportion of patients with disability pro-
gression was 17% in the placebo group as com-
pared with 13%, 13%, and 16% in the twice-
daily BG-12, thrice-daily BG-12, and gla tir a mer 
acetate groups, respectively. In a preplanned sen-
sitivity analysis, 24-week confirmed disability pro-
gression was not significantly reduced versus pla-
cebo in the twice-daily BG-12, thrice-daily BG-12, 
and gla tir a mer acetate groups (38% [P = 0.06], 33% 
[P = 0.12], and 13% [P = 0.55], respectively), with an 
estimated proportion of patients with disability 
progression of 13% in the placebo group versus 
8%, 9%, and 11% in the twice-daily BG-12, thrice-
daily BG-12, and gla tir a mer acetate groups, respec-
tively (Table S3 in the Supplementary Appendix).
MRI End Points
As compared with placebo, twice-daily BG-12, 
thrice-daily BG-12, and gla tir a mer acetate signifi-
cantly reduced the mean number of new or enlarg-
ing hyperintense lesions on T2-weighted images 
at 2 years, by 71%, 73%, and 54%, respectively 
(P<0.001 for all comparisons) (Table 2, and Fig. 
S6A in the Supplementary Appendix), and re-
duced the mean number of new hypointense le-
sions on T1-weighted images, by 57% (P<0.001), 
65% (P<0.001), and 41% (P=0.002), respectively 
(Table 2, and Fig. S6B in the Supplementary Ap-
pendix). The percentage of patients free from new 
or enlarging hyperintense lesions on T2-weighted 
images at 2 years was higher with twice-daily 
BG-12 (27%), thrice-daily BG-12 (31%), or gla tir-
a mer acetate (24%) than with placebo (12%); cor-
responding percentages free from new hypoin-
tense lesions on T1-weighted images were 39%, 
44%, and 34% versus 21%.
The odds of having more gadolinium-enhanc-
ing lesions at 2 years was also significantly reduced 
by twice-daily BG-12, thrice-daily BG-12, and gla-
tir a mer acetate treatment as compared with pla-
cebo, by 74%, 65%, and 61%, respectively 
(P<0.001 for all comparisons) (Table 2, and Fig. 
S6C in the Supplementary Appendix).
Benefits and Risks of BG-12 versus Gla tir a mer 
Acetate
In the prespecified comparison of the relative ef-
ficacy of each active treatment with placebo, the 
estimated treatment effects of both doses of BG-
12 were numerically similar to or larger than those 
of gla tir a mer acetate across efficacy end points 
(Table 2). In a post hoc direct evaluation of the 
relative benefit of BG-12 versus gla tir a mer acetate, 
estimates and 95% confidence intervals excluded 
unity for some comparisons (Fig. S7 in the Supple-
mentary Appendix). Nominal P values for com-
parisons of twice-daily BG-12 and thrice-daily 
BG-12 with gla tir a mer acetate were as follows: an-
nualized relapse rate, P = 0.10 and P = 0.02, re-
spectively; new or enlarging hyperintense lesions 
on T2-weighted images, P = 0.007 and P = 0.002; 
new hypointense lesions on T1-weighted images, 
P = 0.08 and P = 0.003; proportion of patients with 
a relapse, P = 0.58 and P = 0.09; and time to dis-
ability progression, P = 0.44 and P = 0.37.
SAFETY
The overall incidence of adverse events was simi-
lar across study groups (87 to 94%) (Table 3). 
Adverse events reported more frequently with 
BG-12 than with placebo included flushing, gas-
trointestinal events (diarrhea, nausea, and upper 
abdominal pain), upper respiratory tract infec-
tions, and erythema. For flushing, which includ-
ed events of flushing and hot flush, the incidence 
was 35% with twice-daily BG-12 and 28% with 
thrice-daily BG-12 versus 6% with placebo and 3% 
with gla tir a mer acetate; for gastrointestinal events, 
the incidence was 36% with twice-daily BG-12 
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Figure 1. Clinical Outcomes at 2 Years in the Intention-to-Treat Population.
Annualized relapse rates (Panel A) were calculated with the use of a negative binomial regression model, with adjustment for baseline 
score (≤2.0 vs. >2.0) on the Expanded Disability Status Scale (EDDS, which ranges from 0 to 10, with higher scores indicating a greater 
degree of disability), baseline age (<40 years vs. ≥40 years), region (regions were defined on the basis of not only geography but also the 
type of health care system and access to health care in each country), and number of relapses in the 12 months before study entry. Re-
lapses were confirmed by an independent neurologic evaluation committee. The I bars indicate 95% confidence intervals. Hazard ratios for 
time to disability progression (Panel B) were calculated with the use of a Cox proportional-hazards model, with adjustment for baseline 
EDSS score, baseline age (<40 years vs. ≥40 years), and region. The estimated proportions of patients with disability progression at 2 years 
are Kaplan–Meier estimates.
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and 41% with thrice-daily BG-12 versus 26% with 
placebo and 15% with gla tir a mer acetate. Flush-
ing and gastrointestinal events were of mild or 
moderate severity for most patients; the incidence 
of these events was highest in the first month of 
the study, decreasing thereafter (Fig. S8 in the 
Supplementary Appendix). Adverse events report-
ed more frequently in the gla tir a mer acetate group 
than in the placebo group were injection-related 
events: injection-site pain (placebo, 0%; gla tir a-
mer acetate, 8%) and injection-site erythema (pla-
cebo, 0%; gla tir a mer acetate, 9%).
Table 2. Clinical End Points (ITT Population) and MRI End Points (MRI Cohort) during the Study.*
End Point
Placebo 
(N = 363)
Twice-Daily BG-12  
(N = 359)
Thrice-Daily BG-12 
(N = 345)
Glatiramer Acetate 
(N = 350)
Annualized relapse rate at 2 yr†
Rate (95% CI) 0.40 (0.33–0.49) 0.22 (0.18–0.28) 0.20 (0.16–0.25) 0.29 (0.23–0.35)
Percentage reduction vs. placebo (95% CI) 44.0 (26.0–57.7)‡ 50.5 (33.8–63.1)‡ 28.6 (6.9–45.2)§
Time to first confirmed relapse, 25th percentile — wk¶ 30 72 NA‖ 57
Estimated proportion of patients with a relapse at 2 yr
Proportion — %¶ 41 29 24 32
Hazard ratio vs. placebo (95% CI)** 0.66 (0.51–0.86)†† 0.55 (0.42–0.73)‡ 0.71 (0.55–0.92)††
Disability progression at 2 yr
Estimated proportion of patients with progression  
confirmed at least 12 wk later — %¶
17 13 13 16
Hazard ratio vs. placebo (95% CI)‡‡ 0.79 (0.52–1.19) 0.76 (0.50–1.16) 0.93 (0.63–1.37)
New or enlarging T2-weighted hyperintense 
lesions at 2 yr§§
No. of patients evaluated 139 140 140 153
Adjusted mean no. of lesions (95% CI) 17.4 (13.5–22.4) 5.1 (3.9–6.6) 4.7 (3.6–6.2) 8.0 (6.3–10.2)
Ratio of mean no. of lesions in active-treatment group  
to mean no. in placebo group (95% CI)
0.29 (0.21–0.41)‡ 0.27 (0.20–0.38)‡ 0.46 (0.33–0.63)‡
New T1-weighted hypointense lesions at 2 yr§§
No. of patients evaluated 139 140 140 154
Adjusted mean no. of lesions (95% CI) 7.0 (5.3–9.2) 3.0 (2.3–4.0) 2.4 (1.8–3.2) 4.1 (3.2–5.3)
Ratio of mean no. of lesions in active-treatment group  
to mean no. in placebo group (95% CI)
0.43 (0.30–0.61)‡ 0.35 (0.24–0.49)‡ 0.59 (0.42–0.82)‡
Gadolinium-enhancing lesions at 2 yr§§
No. of patients evaluated 144 147 144 161
No. of lesions 2.0±5.6 0.5±1.7 0.4±1.2 0.7±1.8
Odds ratio vs. placebo (95% CI) 0.26 (0.15–0.46)‡ 0.35 (0.20–0.59)‡ 0.39 (0.24–0.65)‡
* Plus–minus values are means ±SD. CI denotes confidence interval, and NA not available.
† Annualized relapse rates were calculated on the basis of negative binomial regression, with adjustment for baseline EDSS score (≤2.0 vs. 
>2.0), baseline age (<40 years vs. ≥40 years), region (regions were defined on the basis of not only geography but also the type of health 
care system and access to health care in each country), and number of relapses in the 12 months before study entry. Relapses were con-
firmed by an independent neurologic evaluation committee.
‡ P<0.001.
§ P<0.05.
¶ Values were calculated with the use of the Kaplan–Meier product-limit method.
‖ The exact estimate was not available because the 25th percentile was greater than 96 weeks.
** Hazard ratios were calculated with the use of a Cox proportional-hazards model, with adjustment for baseline EDSS score (≤2.0 vs. >2.0), 
baseline age (<40 years vs. ≥40 years), region, and number of relapses in the 12 months before study entry.
†† P≤0.01.
‡‡ Hazard ratios were calculated with the use of a Cox proportional-hazards model, with adjustment for baseline EDSS score as a continuous 
variable, region, and baseline age (<40 years vs. ≥40 years).
§§ Patients who were evaluated were patients in the MRI cohort with postbaseline data. Missing data before the use of alternative multiple 
sclerosis medications and visits after patients switched to alternative multiple sclerosis medications were imputed with the use of a constant-
rate assumption. Ratios, relative reductions, 95% CIs, and P values were calculated with the use of negative binomial regression for new 
T2-weighted and new T1-weighted lesions and ordinal logistic regression for gadolinium-enhancing lesions, with adjustment for region and 
baseline T2-weighted lesion volume, T1-weighted lesion volume, or number of gadolinium-enhancing lesions, as appropriate.
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Infections were reported in 56% of patients in 
both BG-12 groups and 50% of patients in the 
placebo and gla tir a mer acetate groups. Infections 
with an incidence that was at least 2 percentage 
points higher in either BG-12 group than in the 
placebo group included nasopharyngitis, urinary 
tract infection, upper respiratory tract infection, 
bronchitis, sinusitis, and gastroenteritis. The inci-
Table 3. Adverse Events (Safety Population).
Event
Placebo
(N = 363)
Twice-Daily BG-12
(N = 359)
Thrice-Daily BG-12
(N = 344)*
Glatiramer Acetate
(N = 351)*
number of patients (percent)
Any adverse event 333 (92) 338 (94) 316 (92) 304 (87)
Most common adverse events†
Multiple sclerosis relapse 155 (43) 110 (31) 85 (25) 119 (34)
Flushing‡ 13 (4) 110 (31) 83 (24) 6 (2)
Nasopharyngitis 58 (16) 62 (17) 63 (18) 51 (15)
Headache 49 (13) 52 (14) 46 (13) 46 (13)
Diarrhea‡ 28 (8) 45 (13) 50 (15) 14 (4)
Urinary tract infection 42 (12) 52 (14) 41 (12) 46 (13)
Nausea‡ 29 (8) 40 (11) 51 (15) 15 (4)
Upper respiratory tract infection‡ 34 (9) 36 (10) 47 (14) 27 (8)
Back pain 33 (9) 35 (10) 36 (10) 32 (9)
Fatigue 33 (9) 37 (10) 33 (10) 30 (9)
Upper abdominal pain‡ 17 (5) 36 (10) 33 (10) 4 (1)
Proteinuria 25 (7) 29 (8) 35 (10) 30 (9)
Depression 35 (10) 24 (7) 15 (4) 30 (9)
Adverse events leading to study-drug discontinuation 38 (10) 44 (12) 41 (12) 35 (10)
Death§ 1 (<1) 0 1 (<1) 1 (<1)
Any serious adverse event 79 (22) 61 (17) 54 (16) 60 (17)
Most common serious adverse events¶
Multiple sclerosis relapse 51 (14) 39 (11) 30 (9) 36 (10)
Gastroenteritis 0 2 (<1) 2 (<1) 0
Cellulitis 0 2 (<1) 1 (<1) 0
Abdominal pain 0 2 (<1) 0 0
Back pain 0 2 (<1) 0 0
Muscle strain 0 0 2 (<1) 0
Depression 0 0 1 (<1) 2 (<1)
Spontaneous abortion 2 (<1) 0 0 0
Anaphylactic reaction 0 0 0 2 (<1)
Convulsion 2 (<1) 0 0 0
Pneumonia 1 (<1) 0 0 2 (<1)
* One patient randomly assigned to the thrice-daily BG-12 group and included in the BG-12 group of the ITT population took glatiramer ace-
tate throughout the study and was therefore counted in the glatiramer acetate group of the safety population.
† These events were reported by at least 10% of patients in any group. The events are listed by decreasing incidence among BG-12–treated patients.
‡ These events had a reported incidence at least 5 percentage points higher in any active treatment group than in the placebo group.
§ Deaths occurring during the study or within 30 days after study withdrawal were due to stroke (placebo group), complications after a multiple 
sclerosis relapse (thrice-daily BG-12 group), and suicide (glatiramer acetate group).
¶ These events were reported by at least two patients in any group. The events are listed by decreasing incidence among BG-12–treated patients.
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dence of serious infections was low and similar 
(1 to 2%) across groups; no opportunistic infec-
tions were reported in any group.
Overall, the incidence of adverse events leading 
to discontinuation of the study drug was similar 
across groups (10% in the placebo group, 12% in 
both BG-12 groups, and 10% in the gla tir a mer 
acetate group) (Table S4 in the Supplementary 
Appendix); discontinuation due to a multiple 
sclerosis relapse was more frequent in the pla-
cebo group (5%) than in the twice-daily BG-12 
group (2%), thrice-daily BG-12 group (<1%), or 
gla tir a mer acetate group (2%). Aside from re-
lapses, the only individual adverse events leading 
to discontinuation of the study drug in more than 
1% of patients in any group were flushing (4% in 
the twice-daily BG-12 group and 2% in the thrice-
daily BG-12 group) and nausea and diarrhea (2% 
each in the thrice-daily BG-12 group).
The incidence of serious adverse events was 
also similar across groups (Table 3). With the 
exception of relapses (which were more common 
in the placebo group than in the other groups), no 
individual serious adverse event was reported in 
more than two patients in any group. No malig-
nant neoplasms were reported in the BG-12 groups; 
one malignant neoplasm was reported in the pla-
cebo group (breast neoplasm), and four malignant 
neoplasms were reported in the gla tir a mer acetate 
group (basal-cell carcinoma, cervical carcinoma, 
endometrial cancer, and thyroid cancer). The in-
cidences of renal, hepatic, and cardiovascular 
events were similar across the four study groups.
In laboratory assessments, mean white-cell and 
lymphocyte counts in both BG-12 groups de-
creased during the first year and then plateaued, 
remaining within the normal range (Fig. S9 in 
the Supplementary Appendix). Mean percentage 
reductions from baseline in white-cell and lympho-
cyte counts were approximately 12% and 32%, 
respectively, in the twice-daily BG-12 group and 
11% and 28% in the thrice-daily BG-12 group at 
1 year. White-cell counts of less than 3.0×109 per 
liter and lymphocyte counts of less than 0.5×109 
per liter (corresponding to National Cancer Insti-
tute Common Toxicity Criteria grade 2 or higher 
and 3 or higher, respectively) were seen in 10% 
and 5%, respectively, of patients in the twice-
daily BG-12 group and in 7% and 4% of patients 
in the thrice-daily BG-12 group, versus 1% and less 
than 1% of patients in the placebo group. One 
patient in the thrice-daily BG-12 group discontin-
ued treatment because of an adverse event asso-
ciated with a low or decreased white-cell count; 
no patients in any group discontinued treatment 
because of an event associated with a low or 
decreased lymphocyte count. The incidence of liver 
aminotransferase levels that were at least three 
times the upper limit of the normal range was 
similar across the study groups; none of these 
elevations were concurrent with bilirubin levels 
that were more than two times the upper limit of 
the normal range (Table S5 in the Supplementary 
Appendix).
Discussion
The CONFIRM study showed that in patients with 
relapsing–remitting multiple sclerosis, BG-12 at a 
dose of 240 mg two or three times daily, as com-
pared with placebo, significantly reduced the rate 
of relapse, the proportion of patients with a re-
lapse, and disease activity as measured by a range 
of MRI end points. These efficacy results are con-
sistent with the results of previous BG-12 stud-
ies14-16 and the Determination of the Efficacy and 
Safety of Oral Fumarate in Relapsing–Remitting 
MS (DEFINE) trial, reported in this issue of the 
Journal, a placebo-controlled, phase 3 study in 
which twice-daily and thrice-daily BG-12 reduced 
the annualized relapse rate by 53% and 48%, re-
spectively, as compared with placebo and reduced 
the estimated proportion of patients with a re-
lapse from 46% with placebo to 27% and 26%, 
respectively.17 Similarly, there were fewer multiple 
sclerosis lesions on MRI scans in patients who 
received BG-12 than in those who received pla-
cebo, in both the CONFIRM and DEFINE stud-
ies. Although both doses of BG-12 had a signifi-
cant effect on disability progression in the 
DEFINE study, neither BG-12 (at either dose) nor 
gla tir a mer acetate had a significant effect on dis-
ability progression in the CONFIRM study. A po-
tential contributor to the difference in findings 
is that in the CONFIRM study, the proportion of 
patients with disability progression in the place-
bo group (17%) was lower than that in the DEFINE 
study (27%).17 BG-12 treatment also resulted in a 
substantial decrease in the number of new hypoin-
tense lesions on T1-weighted images, which are 
characterized by greater axonal loss than isoin-
tense lesions on T1-weighted images.18 This find-
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ing suggests that BG-12 can reduce axonal loss, 
an important pathologic substrate of irreversible 
disability in multiple sclerosis.
These efficacy findings were accompanied by 
broadly similar incidences of adverse events, ad-
verse events leading to discontinuation of the study 
drug, and serious adverse events across all four 
study groups. The most common adverse events 
associated with BG-12 treatment were flushing 
and gastrointestinal events, which were reported 
as mild or moderate in severity by most patients; 
the incidence of these events decreased over time. 
BG-12 was not associated with an increased risk 
of serious infections, opportunistic infections, or 
malignant neoplasms. The safety profile of BG-12 
in the CONFIRM study was similar to that ob-
served in the DEFINE study.
Although our study was not designed to test 
the superiority or noninferiority of BG-12 to gla-
tir a mer acetate, nominal P values for the post hoc 
direct comparison revealed a significantly greater 
treatment effect of BG-12 with respect to the an-
nualized relapse rate (with thrice-daily BG-12), the 
number of new or enlarging hyperintense lesions 
on T2-weighted images (with both BG-12 doses), 
and the number of new hypointense lesions on 
T1-weighted images (with thrice-daily BG-12); none 
of the other comparisons with gla tir a mer acetate 
were significant. Furthermore, our findings with 
respect to the efficacy and safety of gla tir a mer 
acetate were generally consistent with of the re-
sults of previous studies of the drug in relapsing–
remitting multiple sclerosis.19-22
Preclinical studies have shown that dimethyl 
fumarate, through induction of the Nrf2 pathway, 
both reduces inflammatory responses and pro-
vides protection against oxidative stress–induced 
injury.3,23,24 These mechanisms may contribute to 
the beneficial effects observed in patients with 
relapsing–remitting multiple sclerosis, including 
reductions in clinical relapses and MRI measures 
of disease activity with BG-12 in comparison with 
placebo, in both the CONFIRM and DEFINE phase 
3 studies. Overall, these findings support BG-12 
as a potential initial oral treatment for patients 
with relapsing–remitting multiple sclerosis or as 
an alternative to currently available therapies.
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